drugset / Trial / NCT02005458
Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is to examine which dose of YPEG-rhG-CSF, once-per-cycle, has similar efficacy and safety, comparing to PEG-rhG-CSF, once-per-cycle, in chemotherapy-induced neutropenia
Timeline
- Start
- 2013-12
- Primary completion
- 2017-03
- Completion
- 2018-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | PEG-rhG-CSF | Protein / enzyme biologic | 100 ug/kg | Subcutaneous |
| Subject | YPEG-rhG-CSF | Unknown | 20 ug/kg | Subcutaneous |
| Subject | YPEG-rhG-CSF | Unknown | 30 ug/kg | Subcutaneous |
| Subject | YPEG-rhG-CSF | Unknown | 45 ug/kg | Subcutaneous |